BridgeMD
New treatment option for Hepatocellular Carcinoma
Official title Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
ClinicalTrials.gov ID: NCT06609876
What this study is testing
What is Donafenib?
Donafenib is an investigational medicine, being studied as a potential treatment for hepatocellular carcinoma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study intends to evaluate the efficacy and safety of low-dose adjuvant donafenib after thermal ablation for early recurrent HCC within Milan criteria.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- were aged 18-75 years;
- had recurrent HCC (RHCC) diagnosed by imaging studies, the first or the second RHCC;
- RHCC met the Milan criteria, namely single RHCC lesion less than 5 cm in diameter or no more than 3 tumors (each ≤3 cm in diameter);
- the early RHCC (recurrent time \<1 year)
- patients were unwilling to undergo repeat hepatectomy or liver transplantation;
You likely can't join if
- were under 18 years or over 75 years of age;
- primary HCC;
- recurrent HCC beyond Milan criteria;
- RHCC with metastasis or macrovascular tumor thrombus
See the full eligibility criteria
- were aged 18-75 years;
- had recurrent HCC (RHCC) diagnosed by imaging studies, the first or the second RHCC;
- RHCC met the Milan criteria, namely single RHCC lesion less than 5 cm in diameter or no more than 3 tumors (each ≤3 cm in diameter);
- the early RHCC (recurrent time \<1 year)
- patients were unwilling to undergo repeat hepatectomy or liver transplantation;
- had well-preserved liver function, i.e., Child-Pugh class A or B, and prolonged prothrombin time≤5 s;
- patients had an Eastern Cooperative Oncology Group performance status score ≤1.
- Ability to understand the protocol and to agree to and sign a written informed consent document.
- were under 18 years or over 75 years of age;
- primary HCC;
- recurrent HCC beyond Milan criteria;
- RHCC with metastasis or macrovascular tumor thrombus
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, None Selected, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, None Selected, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.